Zacks Research Predicts Lower Earnings for Henry Schein

Henry Schein, Inc. (NASDAQ:HSIC) – Stock analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for Henry Schein in a report released on Wednesday, April 2nd. Zacks Research analyst R. Department now expects that the company will earn $1.19 per share for the quarter, down from their previous estimate of $1.21. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein’s Q2 2025 earnings at $1.19 EPS, FY2025 earnings at $4.83 EPS, FY2025 earnings at $4.83 EPS, Q1 2026 earnings at $1.31 EPS, Q1 2026 earnings at $1.31 EPS, Q2 2026 earnings at $1.35 EPS, Q2 2026 earnings at $1.35 EPS, Q4 2026 earnings at $1.38 EPS, Q4 2026 earnings at $1.38 EPS, FY2026 earnings at $5.29 EPS, FY2026 earnings at $5.29 EPS, FY2027 earnings at $5.69 EPS and FY2027 earnings at $5.69 EPS.

A number of other research firms have also recently issued reports on HSIC. Wells Fargo & Company assumed coverage on Henry Schein in a research note on Friday, February 14th. They issued an “equal weight” rating and a $80.00 target price for the company. Jefferies Financial Group increased their target price on Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and lifted their price target for the company from $69.00 to $84.00 in a research note on Monday, January 6th. UBS Group reduced their price target on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a report on Wednesday, February 26th. Finally, Barrington Research restated an “outperform” rating and set a $90.00 price objective on shares of Henry Schein in a report on Wednesday, February 26th. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Henry Schein currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.10.

Henry Schein Price Performance

HSIC opened at $65.47 on Friday. The stock has a market cap of $8.13 billion, a P/E ratio of 26.94, a P/E/G ratio of 2.13 and a beta of 0.84. Henry Schein has a 12 month low of $63.00 and a 12 month high of $82.49. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The company has a fifty day simple moving average of $73.96 and a 200 day simple moving average of $72.58.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.66 earnings per share.

Hedge Funds Weigh In On Henry Schein

Hedge funds and other institutional investors have recently made changes to their positions in the company. Versant Capital Management Inc raised its position in Henry Schein by 274.6% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $32,000 after purchasing an additional 335 shares in the last quarter. Investment Management Corp VA ADV bought a new position in shares of Henry Schein in the 4th quarter valued at $32,000. Venturi Wealth Management LLC raised its holdings in shares of Henry Schein by 3,347.1% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock worth $41,000 after buying an additional 569 shares in the last quarter. Quent Capital LLC lifted its position in shares of Henry Schein by 91.2% during the 4th quarter. Quent Capital LLC now owns 677 shares of the company’s stock worth $47,000 after buying an additional 323 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in Henry Schein by 23.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock valued at $52,000 after buying an additional 143 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Henry Schein

In related news, Director Philip A. Laskawy sold 2,604 shares of the business’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now owns 24,805 shares of the company’s stock, valued at $1,762,147.20. The trade was a 9.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the sale, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.